NeoSep1 trial takes on deadly newborn infections worldwide
Neonatal sepsis is a major global threat, killing around 800,000 newborns each year.
The NeoSep1 trial is stepping up to tackle this by testing better antibiotic treatments for babies, especially as current drugs are losing their power.
The project brings together researchers from eight countries—including Kenya—to find new ways to save lives.
How the trial works—and why it matters
NeoSep1 is trying out older antibiotics like fosfomycin and flomoxef in fresh combinations on 3,000 infants across eight countries by 2029, with 600 kids from Kenya alone.
By figuring out which mixes work best and how to use them safely, the team hopes to boost survival rates and slow down antibiotic resistance.
If successful, these findings could actually change global treatment guidelines and offer real hope for families facing this crisis.